Testing the homocysteine hypothesis in end-stage renal disease: Problems and a possible solution (Q83006806)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16572120%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Testing the homocysteine hypothesis in end-stage renal disease: Problems and a possible solution (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16572120%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

Hoffer LJ

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16572120%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

language of work or name

English

0 references

publication date

1 May 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16572120%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16572120%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

69

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16572120%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16572120%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

1507-1510

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16572120%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.ki.5000279

18 January 2020

exact match

0 references

cites work

Total homocysteine and cardiovascular disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Homocysteine and arteriosclerosis: subclinical and clinical disease associations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Classical homocystinuria: vascular risk and its prevention

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Homocysteine theory of arteriosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Hyperhomocysteinemia evoked by folate depletion: effects on coronary and carotid arterial function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Hyperhomocysteinemia and cardiovascular disease in uremia: the newest evidence in epidemiology and mechanisms of action.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Mechanisms of the atherogenic effects of elevated homocysteine in experimental models.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Homocysteine and vascular disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Homocyst(e)ine, diet, and cardiovascular diseases: a statement for healthcare professionals from the Nutrition Committee, American Heart Association.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Primary Prevention of Ischemic Stroke

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Recent data are not in conflict with homocysteine as a cardiovascular risk factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

The controversy over homocysteine and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Homocysteine and cardiovascular disease: biological mechanisms, observational epidemiology, and the need for randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Decreased rate of coronary restenosis after lowering of plasma homocysteine levels

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Effect of homocysteine-lowering therapy with folic acid, vitamin B12, and vitamin B6 on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Effect of Homocysteine-Lowering therapy on restenosis after percutaneous coronary intervention for narrowings in small coronary arteries

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Folate therapy and in-stent restenosis after coronary stenting

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Biochemical indicators of B vitamin status in the US population after folic acid fortification: results from the National Health and Nutrition Examination Survey 1999-2000.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Power Shortage: clinical trials testing the "homocysteine hypothesis" against a background of folic acid-fortified cereal grain flour

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Total homocysteine lowering treatment among coronary artery disease patients in the era of folic acid-fortified cereal grain flour

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, Vitamins B6 and B12.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Homocysteine and cardiovascular disease in renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Renoprotection: one or many therapies?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Lowering plasma homocysteine with folic acid in cardiovascular disease: what will the trials tell us?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Pyridoxal 5'-phosphate is an ATP-receptor antagonist in freshly isolated rat cardiomyocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

MC-1 (pyridoxal 5'-phosphate): novel therapeutic applications to reduce ischaemic injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Vitamin B6 and hemodialysis: the impact of high-flux/high-efficiency dialysis and review of the literature

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Homocysteine in uraemia--a puzzling and conflicting story

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Vitamin Intervention For Stroke Prevention trial: an efficacy analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

A tale of two homocysteines--and two hemodialysis units

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Editorial: Renal failure, homocysteine and the pharmacology of vitamin B12.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Hydroxocobalamin reduces hyperhomocysteinemia in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Cobalamin dose regimen for maximum homocysteine reduction in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Comparative effects of hydroxocobalamin and cyanocobalamin on plasma homocysteine concentrations in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Effect of vitamin B12 on homocysteine plasma concentration in hemodialysis patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Response of homocysteine, cystathionine, and methylmalonic acid to vitamin treatment in dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Prevalence and determinants of hyperhomocysteinemia in hemodialysis and peritoneal dialysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Oral vitamin B(12) and high-dose folic acid in hemodialysis patients with hyper-homocyst(e)inemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Homocysteine and methionine metabolism in renal failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Total, free, and protein-bound sulphur amino acids in uraemic patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Nutritional modulation of gene expression and homocysteine utilization by vitamin B12.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021

Homocysteine and methionine metabolism in ESRD: A stable isotope study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000279

7 January 2021